Oculis Holding AG (OCS) Reiterated at Buy by Stifel as Privosegtor Becomes Core Focus

Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented, "We reiterate our Buy on OCS, $40 TP. We hosted management on the road as privosegtor’s pivotal development in neuro-ophthalmology begins in earnest. Privosegtor has become the core focus for its strong, evidence-based potential in neuroprotection, with first pivotal PIONEER-1 in lead indication of AON now enrolling. PIONEER-2 (AON) and PIONEER-3 (NAION) beginning 4Q26, with a possible full MS relapse label achievable via PIONEER-4 in ambulatory relapse. Collectively, the three indications have >$20bn TAM. Separately, licaminlimab’s Ph.2/3 PREDICT-1 readout is expected in Dec-26/Jan-27, with the program targeting outsized efficacy in a TNFR1+ subpopulation with a capital-efficient, potentially-partnerable development path. OCS plans to host an R&D Day later in 4Q26 to provide updates on the status of PREDICT-1 + PIONEER-1/2 and discuss next steps for privosegtor, including the design of the MS program and potential expansion into chronic conditions with alternative formulations (e.g., oral)."

For an analyst ratings summary and ratings history on Oculis Holding AG click here. For more ratings news on Oculis Holding AG click here.

Shares of Oculis Holding AG closed at $9.27 yesterday.

You May Also Be Interested In

• Viridian Therapeutic (VRDN) PT Raised to $43 at Stifel
• Freshworks Inc (FRSH) PT Raised to $17 at UBS
• Gartner (IT) PT Raised to $220 at UBS